Maria Geropeppa

Dr. Maria Geropeppa

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
PTPanagiota Tsagkli
Panagiota Tsagkli
MGMaria Geropeppa
Maria Geropeppa
IPIoanna Papadatou
Ioanna Papadatou
VSVana Spoulou
Vana Spoulou
The emergence of SARS-CoV-2 led to a global health crisis and the burden of the disease continues to persist. The rapid development and emergency authorization of various vaccines, including mRNA-based vaccines, played a pivotal role in mitigating severe illness and mortality. However, rapid viral mutations, leading to several variants of concern, challenged vaccine effectiveness, particularly concerning immune evasion. Research on immunity, both from natural infection and vaccination, revealed that while neutralizing antibodies provide protection against infection, their effect is short-lived. The primary defense against severe COVID-19 is derived from the cellular immune response. Hybrid immunity, developed from a combination of natural infection and vaccination, offers enhanced protection, with convalescent vaccinated individuals showing significantly higher levels of neutralizing antibodies. As SARS-CoV-2 continues to evolve, understanding the durability and breadth of hybrid immunity becomes crucial. This narrative review examines the latest data on humoral and cellular immunity from both natural infection and vaccination, discussing how hybrid immunity could inform and optimize future vaccination strategies in the ongoing battle against COVID-19 and in fear of a new pandemic.

18 November 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
TLTheano Lagousi
Theano Lagousi
DGDESPOINA GKENTZI
DESPOINA GKENTZI
MGMaria Geropeppa
Maria Geropeppa
PTPanagiota Tsagkli
Panagiota Tsagkli
VSVana Spoulou
Vana Spoulou
Pregnancy is characterized by immunological alterations in pregnant women that permit the growth of a semi-allogenic fetus, resulting in greater susceptibility of childbearing women to infections. Furthermore, due to the immaturity of the immune system of neonates, a protection gap is present in early life, leaving neonates and infants vulnerable to infectious diseases with increased morbidity and mortality. Maternal immunization against influenza, pertussis, and, in the context of the COVID-19 pandemic, SARS-CoV-2 has been implemented in several countries, with beneficial effects on both the mother and the offspring. The main protective mechanism of vaccination during pregnancy is transplacental transfer of maternal antibodies. However, recent evidence has implied that the fetal immune system may be influenced beyond passive immunity. This review sheds light on the current status of the routinely administered vaccinations during pregnancy, focusing on the impact of maternal immunization on the priming of the fetal immune system and suggesting future perspectives for the optimization of vaccination strategies.

17 December 2025 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
MGMaria Geropeppa
Maria Geropeppa
PTPanagiota Tsagkli
Panagiota Tsagkli
IPIoanna Papadatou
Ioanna Papadatou
VEVasiliki Efthymiou
Vasiliki Efthymiou
ATAlfredo Tagarro
Alfredo Tagarro
VSVana Spoulou
Vana Spoulou
Background: Corticosteroids are effective adjunct treatment for certain infectious diseases. However, their role in children with community-acquired pneumonia (CAP) remains unclear. We aim to assess the efficacy and safety of adjunct corticosteroid therapy in pediatric CAP. Materials and Methods: A systematic literature search was conducted on MEDLINE to retrieve studies assessing systemic corticosteroid therapy, given alongside antimicrobial regimens, in pediatric CAP (last search date December 31, 2024). Literature screening, quality assessment, and data extraction were conducted by 2 independent reviewers. Heterogeneity and publication bias were detected by I 2 and Egger’s tests. The data were pooled using the random-effects model for the conduction of meta-analysis. Results: Twenty-two articles (N = 75.353) of 3799 screened studies were included in the systematic review; 7 of 22 studies providing data on length of hospital stay (LOS) and duration of fever for corticosteroid-treated versus control patients were included in the meta-analysis. Significant heterogeneity was observed regarding the regimen, dosage and duration of corticosteroid therapy. Regarding meta-analysis, LOS and time to defervescence were significantly decreased in patients receiving corticosteroids compared to controls in randomized clinical trials (Cohen’s d value = −0.59, 95% confidence interval: −0.96 to −0.23, P = 0.001 , I 2 = 52.6%; Cohen’s d value =-0.54, 95% confidence interval: −0.83 to −0.26, P < 0.001 , I 2 = 26.1%, respectively), but not in observational studies. Corticosteroid administration was associated with a shorter radiologic and clinical recovery time especially for Mycoplasma pneumoniae and viral pneumonia with wheezing. Corticosteroid-related adverse events were infrequent and manageable. Conclusions: Our analysis suggests a possible advantage for corticosteroid therapy in selected pediatric patients with CAP. Further studies are needed to clarify how, when, and where corticosteroids should be added to the treatment plan of pediatric CAP.

29 July 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
TLTheano Lagousi
Theano Lagousi
JRJohn Routsias
John Routsias
MMMaria Mavrouli
Maria Mavrouli
IPIoanna Papadatou
Ioanna Papadatou
MGMaria Geropeppa
Maria Geropeppa
VSVana Spoulou
Vana Spoulou
Humoral immunity after SARS-CoV-2 immunization or natural infection is thought to be evanescent. In our study, we aimed to longitudinally characterize the kinetics of antibody titers after dual BNT162b2 immunization or wild-type infection. Vaccinated and recovered individuals displayed distinct antibody kinetics, as convalescents had detectable RBD-, S1-specific, and neutralizing IgG antibody titers two weeks post-infection that gradually increased longitudinally, while RBD-, S1-specific, and neutralizing IgG were detected in vaccinees after the first dose, increased significantly 3 weeks post the second dose and decreased significantly 4–5 months thereafter. Neutralizing IgG was significantly higher initially in convalescent individuals; however, vaccines displayed significantly higher neutralizing antibodies 4–5 months post the second dose. In both groups, there was a strong negative association between elapsed time and antibody levels. The avidity of anti-RBD antibody titers increased significantly in patients longitudinally, while in vaccinees initially increased, with subsequent decrease, remaining however higher than antibody avidity of recovered individuals at all time-points. Anti-RBD antibodies were strongly correlated with neutralizing and anti-S1 antibodies in both groups at all time-points. This study facilitates our further understanding of immune response to SARS-CoV-2 and vaccines.

1 January 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
IPIoanna Papadatou
Ioanna Papadatou
MGMaria Geropeppa
Maria Geropeppa
KVKleio-Maria Verrou
Kleio-Maria Verrou
MTMarianna Tzanoudaki
Marianna Tzanoudaki
TLTheano Lagousi
Theano Lagousi
VSVana Spoulou
Vana Spoulou
Background: mRNA vaccines have played a crucial role in controlling the SARS-CoV-2 global pandemic. However, the immunological mechanisms involved in the induction, magnitude and longevity of mRNA-vaccine-induced protective immunity are still unclear. Methods: In our study, we used whole-RNA sequencing along with detailed immunophenotyping of antigen-specific T cells and humoral RBD-specific response to dual immunization with the Pfizer–BioNTech mRNA vaccine (BNT162b2) and correlated them with response to an additional dose, administered 10 months later, in order to comprehensively profile the immune response of healthy volunteers to BNT162b2. Results: Primary dual immunization induced upregulation of the Type I interferon pathway and generated spike protein (S)-specific IFN-γ+ and TNF-α+ CD4 T cells, S-specific memory CD4 T cells, and RBD-specific antibodies against SARS-CoV-2. S-specific CD4 T cells induced by the primary series correlated with the RBD-specific antibody titers to a third dose. Conclusions: This study demonstrates the induction of both innate and adaptive immunity in response to the BNT162b2 mRNA vaccine in a coordinated manner and identifies the central role of primarily induced CD4+ T cells as a predictive biomarker of the magnitude of anamnestic immune response.

25 June 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
MGMaria Geropeppa
Maria Geropeppa
IPIoanna Papadatou
Ioanna Papadatou
Panagiotis SarantisPanagiotis Sarantis
Panagiotis Sarantis
MTMarianna Tzanoudaki
Marianna Tzanoudaki
Ioannis Ntanasis-StathopoulosIoannis Ntanasis-Stathopoulos
Ioannis Ntanasis-Stathopoulos
VSVana Spoulou
Vana Spoulou
MRNA vaccines have been instrumental in controlling the SARS-CoV-2 pandemic, but the short-lived protection mediated by Receptor Binding Domain (RBD)-specific antibodies necessitates frequent revaccinations to enhance vaccine-induced immunity. The development of RBD-specific B cell memory is critical for improving the qualitative and quantitative characteristics of the immune response. However, the effect of additional doses of mRNA vaccines on the composition of the RBD-specific B cell memory pool remains unclear. In this study, we found that dual BNT162b2 vaccination significantly increased both total RBD-specific and memory RBD-specific B cells and neutralizing antibodies. Following the second BNT162b2 dose, we showed a trend for the enrichment of CD27+IgM− memory RBD-specific B cells, which are known to correlate with a strong humoral response upon re-challenge. Repeated Measures Correlation (rmcorr) analysis revealed a significant correlation between antibody titers and both total and memory RBD-specific B cells, demonstrating that B cell and antibody responses are generated in a coordinated manner following BNT162b2 mRNA immunization. Our findings indicate that additional doses of the BNT162b2 mRNA vaccine enhance the qualitative and quantitative enrichment of the memory B cell pool against the vaccine antigens and collectively demonstrate the induction of a coordinated immune response to mRNA vaccination.